Estimation of Progression Free Survival (PFS) in patients with hormone positive metastatic breast cancer in cohort of Egyptian patients (Retrospective Cohort Study)

Abstract

reast cancer (BC) is the second most common cancer in the world and the most frequent cancer among women. with approximately 1.7 million new cancer cases diagnosed yearly. It is the most common female malignancy accounting for 22.9% and 37.7% of all female cancers worldwide and in Egypt, respectively. BC in Egypt carries an unfavorable prognosis with 29% mortality and 3.7:1 incidence to mortality ratio. Despite improvements in the early detection of breast cancer and the development of more effective systemic therapies, about 30% of patients with early disease will relapse with distant metastases, and metastatic disease remains the leading cause of death in those patients with breast cancer. Most women present with early Breast Cancer and have surgery, with or without radiotherapy, as well as adjuvant systemic therapy to reduce their risk of subsequent relapse. Approximately 5-10 % of women present with distant metastasis at diagnosis. Treatment paradigms for this disease are changing rapidly and mortality is steadily declining, largely due to advances in population screening and early-stage treatments that decrease risk of distant recurrence. Women with metastatic breast cancer (MBC) an estimated three-quarters of whom were diagnosed with stage I–III disease and later developed distant recurrence, and an